Search for: "VITAL PHARMACEUTICALS, INC." Results 1 - 20 of 162
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
10 Jul 2013, 10:14 am by Steven G. Pearl
Vital Pharmaceuticals, Inc., ___ F.3d ___ (7/2/13), the plaintiff filed a putative nationwide class action in Superior Court, alleging that the defendant, Vital, erroneously marketed and labeled its "ZERO IMPACT" protein bars as having little to no impact on blood sugar. [read post]
29 Jun 2009, 12:41 pm
  The plaintiff, Zack Aaronson, is seeking class action status for his lawsuit against Vital Pharmaceuticals, Inc. [read post]
8 Sep 2016, 9:17 am by Lawrence B. Ebert
Overview:Asia Vital Components Co., Ltd. [read post]
4 Aug 2022, 11:18 am by Eileen McDermott
Court of Appeals for the Eleventh Circuit affirmed a district court’s ruling against Vital Pharmaceuticals, Inc. [read post]
4 Aug 2022, 11:18 am by Eileen McDermott
Court of Appeals for the Eleventh Circuit affirmed a district court’s ruling against Vital Pharmaceuticals, Inc. [read post]
31 Aug 2021, 4:15 am by Peter Hess
District Court for the Southern District of Florida ruled against plaintiff Vital Pharmaceuticals, Inc. [read post]
10 Jan 2009, 3:32 am
Vital Pharmaceutical, Inc., 2008 WL 5427601 (S.D. [read post]
12 Aug 2010, 9:40 am by Rebecca Tushnet
Vital Pharmaceutical, Inc., 2010 WL 3069690 (S.D. [read post]
31 Aug 2021, 4:15 am by Peter Hess
District Court for the Southern District of Florida ruled against plaintiff Vital Pharmaceuticals, Inc. [read post]
11 Sep 2012, 9:28 am by Rebecca Tushnet
Vital Pharmaceuticals, Inc., 2012 WL 3881599 (E.D. [read post]
15 May 2013, 4:45 am
Bankosky worked for Takeda Pharmaceuticals International, Inc., first as a director of Global Licensing and Business Development and then as a senior director. [read post]
15 Jan 2013, 11:33 am by Ed Silverman
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]